New clinical & biological insights at long-term follow up of the TARGIT-A randomised trial of risk-adapted single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for breast cancer

Jayant S Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael Alvarado, Michael Douek, Christobel Saunders, Henrik Flyger, Wolfgang Eiermann, Chris Brew-Graves, Norman Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen, Gloria Petralia, Mary Falzon, David Joseph, Jeffrey S Tobias

Radiotherapy during lumpectomy for breast cancer is better for patients #RCT

- ✓As effective as whole breast radiotherapy for breast cancer control
- ✓Substantially fewer deaths from cardiovascular causes and other cancers

Non-breast cancer mortality reduced from 9.9% to 5.4% at 12 years

- ✓Surgery & radiotherapy completed at the same time
- ✓Less pain
- ✓Less travel
- ✓Less time off work or play
- ✓⇧Access to breast conservation
- ✓Improved cosmetic outcome
- ✓Fewer complications
- ✓Lower toxicity
- ✓Lower cost

- ✓TARGIT-IORT found effective in all ductal subtypes
- ✓Effective despite many high-risk cases, 488 (22%), 443 (20%) grade 3, node+, 426 (19%) ER/PgR neg
- ✓Improved *overall* survival if grade 1 or 2, reducing overall mortality from 15.1%→ 10.7% at 12 years
- ✓A decision-aid for adding EBRT https://targit.org.uk/addrt
- ✓Unlike EBRT, the hazard of breast cancer death is not increased with local relapse after TARGIT-IORT
- ✓TARGIT-IORT reduces non-breast cancer mortality even when additional EBRT is given

The TARGIT-A international randomised controlled trial

FUNDED BY NIHR | National Institute for Health Research



2298 patients from 32 centres, 10 countries

The first patient randomised – 24 Mar 2000

Data lock for long-term outcomes – 3 Jul 2019

95% patients had at least 5-year follow up AND 90% patients had either 10-year follow up or had been seen within previous year

First results 2010

THE LANCET

"For selected patients with early breast cancer, a single dose of radiotherapy delivered at the time of surgery by use of targeted intraoperative radiotherapy should be considered as an alternative to external beam radiotherapy delivered over several weeks."



Fewer Non-breast cancer deaths



Improved overall survival if Grade 1 or Grade 2, n=1797



Does avoiding EBRT reduce non-breast cancer deaths?



Does giving TARGIT-IORT reduce non-breast cancer deaths?



Mortality unchanged even if grade 3, n=443



Excellent prognosis even after LR



More info https://targit.org.uk

Any questions? Scan to contact us →